On October 26, 2022 Alkermes plc (Nasdaq: ALKS) reported that it will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Wednesday, Nov. 2, 2022 to discuss the company’s third quarter financial results (Press release, Alkermes, OCT 26, 2022, View Source [SID1234622437]). Management will also provide an update on the company .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.

On October 26, 2022 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that it will report its 2022 third quarter financial results on Wednesday, November 9, 2022, after the close of the U.S. financial markets (Press release, Jazz Pharmaceuticals, OCT 26, 2022, View Source [SID1234622436]). Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 third quarter financial results and provide a business and financial update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

On October 26, 2022 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) reported that it will release results for the third quarter 2022 on Wednesday, November 2, 2022, after the market closes (Press release, Vanda Pharmaceuticals, OCT 26, 2022, View Source [SID1234622435]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vanda will host a conference call at 4:30 PM ET on Wednesday, November 2, 2022, during which management will discuss the third quarter 2022 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 5456289.

The conference call will be broadcast simultaneously and archived on Vanda’s website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, November 2, 2022, beginning at 8:30 PM ET and will be accessible until Wednesday, November 9, 2022, at 8:30 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 5456289.

On October 26, 2022 Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization, reported its fiscal year 2022 third-quarter financial results, reported that the company’s cumulative revenue in fiscal year 2022 surpassed KRW 2 trillion (Press release, Samsung BioLogics, OCT 26, 2022, View Source [SID1234622434]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

John Rim, CEO of Samsung Biologics, said: "This past quarter saw strong performance and growth due to a consistent momentum in signing new contracts, helping us meet client demand for integrated offerings and deliver long-term value. Not only have we delivered on our commitments by commencing GMP operations of Plant 4 within just 23 months from the start of its construction, we have also developed and launched our next-generation bio-technologies – S-DUAL and DEVELOPICK – which will help streamline and accelerate the antibody development process to save time and cost for our clients."

THIRD QUARTER 2022 RESULTS

Samsung Biologics in the third fiscal quarter recorded a consolidated revenue of KRW 873 billion, operating profit of KRW 324.7 billion, and net profit of KRW 129.2 billion.

FOURTH QUARTER & FISCAL YEAR 2022 OUTLOOK

As previously announced, Samsung Biologics commenced GMP operations of Plant 4, the world’s largest single bio-manufacturing plant, within just 23 months since its groundbreaking. The construction of the 240,000-liter CDMO plant is expected to be completed in 2023, designating Samsung Biologics as the top global manufacturing hub with a total capacity of 604,000 liters, a volume equivalent to over one-fourth of worldwide CMO capacity.

Samsung Biologics launched its new proprietary development technology platforms – S-DUAL and DEVELOPICK – a high-yield bispecific antibody platform and a rapid developability assessment platform.

Samsung Biologics also achieved several business milestones, including the signing of a land-purchasing agreement for Bio Campus II with 30% greater land area for additional capacity and platform growth. Then in August, a $15 million investment through the Samsung Life Science Fund, a joint venture with Samsung C&T, was granted to Senda Biosciences, a U.S.-based biotechnology company committed to fostering core technologies needed to develop next-generation biopharmaceuticals.

In September, Samsung Biologics received EcoVadis’ Gold Sustainability Rating in recognition of its ongoing sustainable management efforts, placing the company within the top 5 percentile.

For more details on performance and financials, please refer to the Earnings Release.

On October 26, 2022 AI Metrics, an early stage AI-enabled, cancer-imaging radiology software company, reported that it has raised $1.26MM in a bridge financing round (Press release, Metrics, OCT 26, 2022, View Source [SID1234622433]). The round was led by an angel fund and several individual investors, many of them leading radiologists.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AI Metrics was launched in 2019 by Bob Jacobus, Paige Severino, and radiologist and researcher Dr. Andrew Smith. The company has been developing software to more accurately assess cancer treatment effectiveness — leveraging augmented intelligence to improve radiology workflows and deliver detailed updates of therapy progress to oncologists and patients.

"We are excited to have a mix of existing and new investors support AI Metrics, including several radiologists who are attracted to our promising and innovative technology," said Bob Jacobus, CEO. "AI Metrics expanded its investor base with field experts eager to capitalize on what they see as a breakthrough technology coming to market."

AI Metrics plans to invest in R&D resources to continue its quest to help radiologists deliver improved speed, accuracy, consistency, and clarity of patient condition.